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Colorectal cancer is a heterogeneous disease at the histomorphological, clinical and molecular level. Approximately 20% of
cases may progress through the “serrated” pathway characterized by BRAF mutation and high-level CpG Island Methylator
Phenotype (CIMP). A large subgroup are additionally microsatellite instable (MSI) and demonstrate significant loss of tumor
suppressor Cdx2. The aim of this study is to determine the specificity of Cdx2 protein expression and CpG promoter hyper-
methylation for BRAFV600E and high-level CIMP in colorectal cancer. Cdx2, Mlh1, Msh2, Msh6, and Pms2 were analyzed by
immunohistochemistry using a multi-punch tissue microarray (TMA; n 5 220 patients). KRAS and BRAFV600E mutation analysis,
CDX2 methylation and CIMP were investigated. Loss of Cdx2 was correlated with larger tumor size (P 5 0.0154), right-sided
location (P 5 0.0014), higher tumor grade (P < 0.0001), more advanced pT (P 5 0.0234) and lymphatic invasion (P 5
0.0351). Specificity was 100% for mismatch repair (MMR)-deficiency (P < 0.0001), 92.2% (P < 0.0001) for BRAFV600E and
91.8% for CIMP-high. Combined analysis of BRAFV600E/CIMP identified Cdx2 loss as sensitive (80%) and specific (91.5%) for
mutation/high status. These results were validated on eight well-established colorectal cancer cell lines. CDX2 methylation
correlated with BRAFV600E (P 5 0.0184) and with Cdx2 protein loss (P 5 0.0028). These results seem to indicate that Cdx2
may play a role in the serrated pathway to colorectal cancer as underlined by strong relationships with BRAFV600E, CIMP-high
and MMR-deficiency. Whether this protein can only be used as a “surrogate” marker, or is functionally involved in the pro-
gression of these tumors remains to be elucidated.
In 1999, the group of Issa et al. deﬁned a novel phenotype in
colorectal cancer based on widespread CpG island methyla-
tion: the CpG Island Methylator Phenotype (CIMP).1 In
colorectal cancer and other tumor types, this aberrant
methylation of promoter region CpG islands is associated
with transcriptional inactivation of tumor suppressor genes,
and is intimately involved in tumor progression.2–4
Despite variations in methodologies for the assessment of
CIMP such as differences in gene panels and methods of
analysis,5 most studies have shown an incremental worsening
in prognosis in patients with high-level CIMP.6–10 At the
clinical and histomorphological level, CIMP-high colorectal
cancers tend to occur more frequently in the right colon.11
They may have more mucinous histology and are poorly dif-
ferentiated.12,13 Association of CIMP-positivity with some
environmental factors has been identiﬁed such as cigarette
smoking and folic acid intake, the latter suggesting a possible
interaction with 5-FU-based therapies.14,15 Indeed, CIMP sta-
tus has also been explored as a putative predictive biomarker
in several studies; high-level CIMP may have a positive bene-
ﬁt in patients treated with 5-FU-based chemotherapy.16–18
Most striking about CIMP-high colorectal cancers are
their associations at the molecular level with BRAF muta-
tion,13,19,20 CDKN2A (p16INK4A)21,22 and microsatellite
instability (MSI).20,23 These relationships have led to the pro-
posal of different models of colorectal cancer progression
based on mutation, methylation and MSI. In one such model,
20% of colorectal cancers are thought to arise through the
serrated pathway. BRAF mutation in a ﬁrst step is thought to
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induce normal epithelium to undergo an initial cellular pro-
liferation which is followed by senescence.24 In a second step,
oncogene-activated cell senescence may be overcome by
methylation-induced silencing of CDKN2A or other mecha-
nisms such as p53 loss leading to the development of a pre-
neoplastic lesion, i.e., the sessile serrated adenoma, or
serrated polyp and then ﬁnally to cancer.25 Importantly,
among the relevant tumor suppressor genes frequently
silenced by CIMP is MLH1, a critical gene involved in DNA
mismatch repair. When hypermethylated, MLH1 contributes
to the development of MSI, a feature observed in 15% of all
colorectal cancers. Minoo and Jass could show that BRAF
mutation was causally related to MSI in colon cancer cell
lines.26 Most recently, the existence of the serrated pathway
as a consequence of BRAF mutation and direct relationship
to MSI was shown in vivo using a novel BRAF-mutant
mouse model of intestinal pathology.27
A particular feature of MSI-high colorectal cancers is its
relationship to Cdx2, a homeodomain transcription factor
which functions to regulate intestinal epithelial cell differen-
tiation.28 Because the expression of Cdx2 is almost entirely
restricted to the gastrointestinal tract, it is used as a marker
for the identiﬁcation of tumors of intestinal origin in daily
diagnostic routine.29 However, our group and others have
demonstrated that mismatch repair (MMR)-deﬁcient or MSI-
high colorectal cancers have signiﬁcant losses of Cdx2 expres-
sion.30 Furthermore, Cdx2 loss has been associated with
more aggressive histomorphological features, unfavorable sur-
vival time and could act as a marker for both BRAFV600E
mutation and CIMP-high status.13,31,32
On the basis of these ﬁndings, we hypothesize that loss of
Cdx2 expression is speciﬁc to tumors characterized by
BRAFV600E mutation and CIMP-high (and therefore by exten-
sion MSI-high) and therefore may serve as a marker for the ser-
rated pathway. The aim of this study is to determine whether
Cdx2 loss is associated with adverse clinicopathological features
and is speciﬁc for MSI, BRAFV600E mutation and CIMP-high
status. In a second aim, we investigate CDX2 hypermethylation
as a possible cause of reduced Cdx2 expression.
Patients and Methods
Patients
The patient cohort consisted of 220 patients with primary
colorectal cancers treated at the Fourth Department of Sur-
gery, University of Athens Medical School in Athens, Greece,
between 2002 and 2007. Complete histopathological and clin-
ical information was retrospectively collected for each patient
including pT, pN, pM, tumor grade, histological subtype,
venous invasion and lymphatic invasion. TNM staging was
performed according to the 6th ed. of the AJCC/UICC man-
ual. Tumor budding was assigned as low- or high-grade
according to a reproducible method.33 Survival time and
information on adjuvant therapy was available. No patient
received preoperative therapy. Overall median survival time
for the cohort was 60 months.
Specimen characteristics
Formalin ﬁxed (10% neutral buffered formalin) parafﬁn-
embedded tumor blocks were retrieved from the correspond-
ing institute of pathology. One representative tumor block was
identiﬁed for tissue microarray (TMA) construction, immuno-
histochemistry and subsequent DNA extraction. Additionally,
17 cases of sessile serrated adenomas (SSA) or tubular adeno-
mas (TAs) were selected and re-reviewed. These included
7 SSAs, 9 TAs with low-grade dysplasia, and 1 mixed case of
TA with a small focus of high-grade dysplasia (5%) /SSA. Eth-
ical consent was obtained from the local ethics commission.
Cell lines
In addition to colorectal cancer tissues, eight well-established
human colon cancer cell lines were included in this study
(HCT15, SW620, LS174, LS180, SW480, HCT116, COLO205,
HT29). Cells were harvested after trypsinization in a solution
of 0.05% of Trypsin-EDTA and washed two times in PBS-
buffer. Four drops of serum were added to the cell sediment
and mixed to dissolve the pellet. One drop of thrombin was
then added to the solution and incubated for 2 min at room
temperature until a clot was formed. The clot was transferred
into a plastic cassette and incubated in 4% formalin. After
dehydration in graded alcohols and immersion in xylene,
parafﬁn-embedding of each cell line was undertaken and a
cell block was made. A TMA containing two punches per
cell lines was constructed (total 5 16 cores).
Immunohistochemistry
Immunohistochemistry for Cdx2 as well as for MMR
proteins Mlh1, Msh2, Msh6, and Pms2 was performed on
the multi-punch tissue microarray with an average of four
tumor cores per patient. Protocols for all stains have been
What’s new?
Some colorectal cancers have aberrant methylation of CpG islands, mutations in the BRAF gene, and deactivation of the tumor
suppressor Cdx2. Previous studies have shown that patients with CpG methylation do worse than those without. This study
sought to determine whether loss of Cdx2 also means poorer outcomes, and how it correlates with CpG methylation and BRAF
mutation. Without Cdx2, they found, tumors grew larger and attained a higher grade; loss of Cdx2 also strongly predicted
BRAF mutation and CpG methylation, and methylation of the CDX2 gene correlated with Cdx2 protein loss. Cdx2 might, there-
fore, play a role in spurring colorectal cancer.
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previously described.34 For Cdx2, the average percentage of
expression was determined across all tumor punches and
ranged from 0 to 100%. MMR protein expression was deﬁned
as positive when any staining in any tumor punch was
observed. Negativity for a MMR protein was deﬁned when
all tumor punches for that marker were 0%. A patient was
then classiﬁed as MMR-deﬁcient when at least one of the
four proteins was negative. Because information on family
history was unavailable, no attempt was made to further sub-
divide patients into Lynch syndrome or sporadic MSI. Cdx2
immunohistochemistry was additionally performed on the
cell line TMA and on all 17 adenoma cases.
CDX2 mRNA in situ hybridization
mRNA in situ hybridization (ISH) for CDX2 was performed
on the colorectal cancer patient TMA using probes from
RNA ScopeVR (VS Probe-Hs-CDX2, NM_001265.4, probe
region: 901-1803, Advanced Cell Diagnostics, Hayward, CA)
on an automated platform (Discovery Ultra, Ventana, Rotk-
reuz, Switzerland). A negative control using DapB (dihydro-
dipicolinate reductase gene) mRNA expression of Bacillus
subtilis and a “moderately” expressing positive control PPIB
(peptidylprolyl isomerase B) were used. The following score
was employed to determine the semi-quantitative expression
of CDX2 mRNA per TMA punch: score 0 5 no staining,
score 1 5 difﬁcult to see under 403, score 2 5 difﬁcult to
see under 203 but easy under 403, score 3 5 difﬁcult to see
under 103 but easy under 203 and score 4 5 easy to see
under 103.
Molecular analysis
DNA extraction. DNA was extracted from each primary
colorectal cancer. First, the corresponding Hematoxylin and
Eosin (H&E) stained slides were reviewed and areas of
tumorous tissue were marked. A minimum of ﬁve whole tis-
sue sections from each case were cut from corresponding
parafﬁn-embedded tissue blocks at 4 mm. Slides were
scratched using a scalpel in designated regions. DNA was
extracted using standard protocols (FFPE Kit, Qiagen).
Mutation and methylation analysis by pyrosequencing. All
analyses were carried out using the pyrosequencing method.
BRAF (exon 15, V600E mutations) and KRAS (exon 2, codon
12 and 13) mutations were interrogated. For CpG methyla-
tion analysis, bisulﬁte conversion of all DNA samples was
undertaken using the EpiTect Bisulﬁte Conversion Kit (Qia-
gen) according to manufacturer’s instructions. The
Hs_CDX2_03 assay from Qiagen containing forward and
reverse (biotinylated) primers was used for the investigation
of CDX2 hypermethylation. The sequence to analyze was 50-
GGCGACGGGGGCGCGCCCCGT-30 and contained 5 CpG
sites located at Chr 13:28541900-28542023. A representative
pyrogram for this CDX2 assay is illustrated in Figure 1a.
Ampliﬁcation by PCR was performed using 45 cycles at
56C. CpG analysis for SOCS1, NEUROG1, MLH1,
CRABP1A, CDKN2A, and RUNX3 were also carried out
using 45 ampliﬁcation cycles at 56C for all primers except
NEUROG1 (57C). Primer sequences are listed in Supporting
Information Table 1. Following PCR, fragment analysis was
Figure 1. (a) Representative pyrogram of CDX2 CpG methylation assay. (b) Study design. (c) Cdx2 positive colorectal cancer with positive
internal control. (d) Cdx2 negative cancer with positive internal control. [Color figure can be viewed in the online issue, which is available
at wileyonlinelibrary.com]
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carried out using the QIAxcel system (Qiagen). In prepara-
tion for pyrosequencing, immobilization of PCR products by
binding of biotin to streptavidin coated Sepharose beads (GE
Healthcare) was performed. A Master Mix containing a mini-
mum of 2 ml/sample of beads, 40 ml/sample of binding buffer
and 18–33 ml/sample of high-purity water was added to 5–20
ml PCR product into a PCR plate to a total volume of 80 ml.
The plate was shaken for 10 minutes at room temperature.
About 25 ml of 0.3 mM sequencing primer was pipetted onto
a PyroMark Q24 Plate. Both PCR and Q24 plates were
placed into their designated positions on the vacuum work-
station. With the workstation pump on, the vacuum tool was
used for 15 sec to capture beads with PCR product then low-
ered into 70% ethanol for 5 sec, denaturation solution for
5 sec and wash buffer for 10 sec. The vacuum tool was
aligned with the Q24 plate containing the sequencing primer
then switched off to allow for single stranded PCR products
to make contact with sequencing primers. Annealing of
sequencing primers to DNA strands was performed by heat-
ing the Q24 plate for 2 min on a heating block at 80C. After
cooling for 5 min, the plate was inserted into the PyroMark
Q24 instrument for pyrosequencing. Bisulﬁte controls were
included into the program for each assay manually to ensure
complete conversion of DNA. In addition, a control oligo
and water control was used in every pyrosequencing run. For
each assay, the ratio of C:T indicating the percentage of
methylated to nonmethylated C residues at each CpG site
was noted. Then an average percentage of methylation across
each case was determined. For each gene, the 75th-percentile
was used as a cutoff to determine “hypermethylation” status.
CIMP-high was deﬁned by at least 3/6 hypermethylated
genes, CIMP-low as at most 2/6 hypermethylated genes and
CIMP-negative as 0/6 hypermethylated genes.
Study design
The study design is outlined in Figure 1b. The patient cohort
was used to identify whether Cdx2 loss by immunohisto-
chemistry on a multipunch tissue microarray and methyla-
tion analysis in primary colorectal cancers is related to
poorer prognosis and more adverse clinicopathological fea-
tures, MMR status, KRAS and BRAFV600E mutation as well
as CIMP status. Additional mRNA ISH for CDX2 was per-
formed. Inclusion of eight well-established colorectal cancer
cell lines after parafﬁn embedding and TMA construction
allowed the study of Cdx2 expression and correlation with
molecular features. Additionally, 17 cases of adenomas were
investigated for Cdx2 protein expression.
Statistics
The association between Cdx2 expression as continuous vari-
able and categorical clinicopathological features including tumor
location (left/rectum vs. right), histological subtype (nonmuci-
nous vs. mucinous), tumor grade (G1/G2 vs. G3), pT (pT1-2
vs. pT3-4), pN (pN0 vs. >pN0), pM (pM0 vs. >pM0), venous
invasion (V0 vs. >V0), lymphatic invasion (L0 vs. >L0), tumor
budding (low-grade vs. high-grade), MMR status (proﬁcient vs.
deﬁcient), KRAS and BRAFV600E (wild-type vs. mutation) and
CIMP status (negative/low vs. high) was investigated using sim-
ple logistic regression analysis. Odds ratio (OR) and 95% conﬁ-
dence intervals (CI) were used to determine effect size. The
Area under the ROC curve (AUC) was used to determine the
discriminatory ability of Cdx2 expression for each feature, with
values closer to 1.0 indicating a better discrimination. For the
association with age and tumor size, linear regression analysis
was used. The R-squared value was obtained. Cutoff for Cdx2
expression for analysis with BRAFV600E and CIMP status was
determined using classiﬁcation and regression tree analysis
(CART) with a 10-fold cross-validation method. Chi-Square
test was used for the relationship between Cdx2 low/high and
BRAFV600E and/or CIMP status and for analysis of hypermeth-
ylation and clinicopathologcial features. p values <0.05 were
considered statistically signiﬁcant. All analyses were carried out
using SAS V9.2 (The SAS Institute, Cary, NC).
Results
Patient characteristics
Patient characteristics are summarized in Table 1. Tissues
from 220 patients were included for Cdx2 expression analysis
using a multi-punch tissue microarray and for CDX2 methyla-
tion analysis, MMR status, BRAF mutation and CIMP status.
Representative photomicrographs for Cdx2 expression are
shown in Figures 1c and 1d. An overview of the degree of
methylation for SOCS1, NEUROG1, MLH1, CDKN2A, CRAB-
PIA and RUNX3 in addition to CDX2 is outlined in the heat
map in Figure 2. For each gene included in the CIMP panel,
the 75th-percentile was used as a threshold to consider the
gene as hypermethylated. Then, a case was designated as
CIMP-high when at least 3/6 genes were above this threshold.
Cdx2 expression and clinicopathological features
Table 2 underlines the associations between reduced Cdx2
expression within colorectal cancers and association with his-
tomorphological, and molecular features. Reduced Cdx2
expression was signiﬁcantly associated with larger tumor size
(p 5 0.0154), right-sided tumor location (p 5 0.001), muci-
nous histology (p 5 0.0069), higher tumor grade (p <
0.0001), more advanced pT classiﬁcation (p 5 0.0234), lym-
phatic invasion (p 5 0.0351), and high-grade tumor budding
(p 5 0.0131). Moreover, MMR deﬁciency (p < 0.0001),
BRAFV600E mutation (p < 0.0001) and CIMP-high status
(p 5 0.0051) were related to decreased expression of Cdx2 in
tumors. There was no association with survival.
Sensitivity, specificity, positive and negative predictive
values of Cdx2 for MMR-deficiency, BRAFV600E and
CIMP-high
Using CART analysis-derived cutoff scores for Cdx2 expres-
sion, a signiﬁcant loss of Cdx2 expression was considered as
90% for MMR-deﬁciency and 25% expression for
BRAFV600E and CIMP-high. In Table 3, all 14 cases with
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MMR-deﬁciency were Cdx2 low while and 100% of all Cdx2
high cases were MMR-proﬁcient. Low and high Cdx2 was cor-
related with BRAFV600E status, CIMP status and combined
BRAF/CIMP status. Of the 13 cases with low Cdx2 expression,
5 were mutated. Although the sensitivity and PPV values were
55.6 and 38.5%, the speciﬁcity and NPV for BRAFV600E muta-
tion were 92.2 and 95.9%. Similar results were obtained for
CIMP-high status. For patients with BRAFV600E mutated and
simultaneous CIMP-high tumors, (n 5 5), four could be pre-
dicted by low Cdx2 expression. Sensitivity was 80% with speci-
ﬁcity, PPV and NPV of 91.5, 30.8, and 99%, respectively.
Cdx2 staining on a colorectal cancer cell line TMA
Immunohistochemistry for Cdx2 was additionally performed
on eight colorectal cancer cell lines after embedding in paraf-
ﬁn and construction of a TMA. Cdx2 expression was corre-
lated with BRAF mutation, CIMP status and MSI status.
Representative photomicrographs are shown in Figure 3.
CDX2 expression was completely negative in LS174,
COLO205, HT29, and HCT116 but positive in HCT15,
LS180, SW480, and SW680. Cdx2 negativity predicted BRAF
mutation status correctly in 6/8 cell lines, CIMP-high status
in 6/8 cell lines and MSI status in 4/8 cases. In a hierarchy
composed of BRAF mutation, followed by CIMP-H and
MSI-H, Cdx2 protein expression was predictive in all 8/8 cell
lines.
Figure 2. Heat map illustrating the degree of methylation of
SOCS1, NEUROG1, MLH1, CDKN2A, CRABP1A, RUNX3, and CDX2.
Red indicates higher percentages of methylation while green repre-
sents lower percentages. Empty spaces indicate non-evaluable
result. For each gene in the CIMP panel to be considered hyperme-
thylated, we used the 75th-percentile. A case was considered
CIMP-H if at least 3/6 genes were hypermethylated. [Color figure
can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
Table 1. Patient characteristics (n 5 220)
Frequency N (%)
Gender Male 102 (48.6)
Female 108 (51.4)
Age (years) Median (range) 71 (35–93)
Tumor size (cm) Median (range) 4.5 (1–12)
Tumor location Left 127 (60.5)
Right 28 (13.3)
Rectum 55 (26.2)
Histological subtype Non-mucinous 185 (88.1)
Mucinous 25 (11.9)
Tumor Grade G1-2 132 (62.9)
G3 78 (37.1)
pT pT1-2 53 (25.2)
pT3-4 157 (74.8)
pN pN0 105 (50.0)
pN1-2 105 (50.0)
Metastasis at diagnosis pM0 188 (89.5)
pM1 22 (10.5)
Venous invasion Presence 40 (18.7)
Absence 174 (81.3)
Lymphatic invasion Presence 86 (40.8)
Absence 125 (59.2)
Tumor budding Low-grade 114 (53.8)
High-grade 98 (46.2)
Adjuvant therapy None 76 (35.5)
Treated 138 (64.5)
MMR status Proficient 196 (91.6)
Deficient 18 (8.4)
KRAS Wild-type 142 (67.0)
Mutation 70 (33.0)
BRAF Wild-type 186 (90.3)
V600E mutation 20 (9.7)
CIMP Negative/low 102 (87.9)
High 14 (12.1)
Survival time (months) Median (95%CI) 60 (48–65)
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CDX2 hypermethylation and clinicopathological features
Methylation analysis was successfully performed in 181 cases
(Table 4). Hypermethylation was observed in 15/181 (8.3%)
tumors. Although not associated with any clinicopathological
feature, methylation was signiﬁcantly more frequent in
BRAFV600E mutated cancers. In addition, hypermethylation
of CDX2 was strongly related to low Cdx2 protein expression
and found in 28.6% of cases in comparison to only 6.1% of
negative/low methylated tumors (p 5 0.0028).
CDX2 protein expression, RNA expression and DNA
methylation
The percentage of Cdx2 protein expression and CDX2 hyper-
methylation is shown in Supporting Information Figure 1a
for each case. The graph outlines an inverse relationship
between the two variables. Particularly, tumors with <20%
Cdx2 protein expression seem to discriminate more from less
heavily methylated cases. The difference in the average meth-
ylation in cases with <20% or 20% protein expression was
signiﬁcant (p 5 0.0073; average methylation 18% vs. 6.3%,
respectively). The ROC curve underlining these ﬁndings is
shown in Supporting Information Figure 1b and suggests that
a possible threshold of 20% for methylation may best retain
its speciﬁcity for protein expression loss at <20% as well.
To resolve any discrepancy between DNA methylation
and protein expression, additional RNA ISH for CDX2 was
performed on the patient tissue microarray. Four hundred
and eighty ﬁve tumor spots could be evaluated for RNA and
Table 2. Association of Cdx2 expression in tumor and clinicopathological features
OR (95%CI) p value AUC Comment
Sex 0.993 (0.981–1.006) 0.2747 0.534
Age1 0.034 6 0.036 0.3514 0.00432
Tumor size1 20.015 6 0.006 0.0154 0.032 Loss of Cdx2 correlated with larger tumor diameters
Tumor location 0.978 (0.965–0.992) 0.0014 0.652 Loss of Cdx2 in right-sided tumors
Histological subtype 0.977 (0.961–0.994) 0.0069 0.668 Loss of Cdx2 in tumors with mucinous histology
Tumor grade 0.969 (0.955–0.983) <0.0001 0.664 Loss of Cdx2 in G3 vs. G1-2 tumors
pT classification 0.98 (0.964–0.997) 0.0234 0.605 Loss of Cdx2 in pT3-4 vs. pT1-2 tumors
pN classification 0.99 (0.977–1.003) 0.1156 0.557
pM classification 1.006 (0.985–1.029) 0.5622 0.554
Venous invasion 0.994 (0.978–1.011) 0.4953 0.555
Lymphatic invasion 0.987 (0.974–0.999) 0.0351 0.568 Loss of Cdx2 in L1 vs. L- tumors
Tumor budding 0.984 (0.972–0.997) 0.0131 0.582 Loss of Cdx2 in high-grade tumor budding cases
MMR status 0.961 (0.942–0.98) <0.0001 0.766 Loss of Cdx2 in MMR-deficient cancers
KRAS status 0.996 (0.983–1.009) 0.5517 0.569
BRAF status 0.961 (0.943–0.979) <0.0001 0.734 Loss of Cdx2 in BRAF mutated tumors
CIMP status 0.967 (0.944–0.991) 0.0069 0.718 Loss of Cdx2 in CIMP-high tumors
1Linear regression analysis was performed. Parameter estimates with SE.
2R-squared value is shown.
Table 3. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) of CDX2 for BRAF mutation, CIMP-high, BRAF mutation/
CIMP-high status
CDX2
p value Sensitivity Specificity PPV NPVLow High
MMR status Proficient 30 (68.2) 48 (100.0) <0.0001 100% 61.5% 31.8 100%
Deficient 14 (31.8) 0 (0.0)
BRAF Wild-type 8 (61.5) 94 (95.9) <0.0001 55.6% 92.2% 38.5% 95.9%
V600E mutation 5 (38.5) 4 (4.1)
CIMP Negative/low 8 (61.5) 90 (91.8) 0.0076 38.5% 91.8% 38.5% 91.8%
High 5 (38.5) 8 (8.2)
BRAF/CIMP WT or N/L 9 (69.2) 97 (99.0) <0.0001 80% 91.5% 30.8% 99%
V600E mutation and high 4 (30.8) 1 (1.0)
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protein (Supporting Information Fig. 2). The correlation
coefﬁcient was r 5 0.41 (p < 0.0001) indicating a relatively
strong positive relationship between protein and gene expres-
sion in tumor samples. Of the 80 tissue spots with <20%
Cdx2 protein expression, 38 (47.5%) had an RNA ISH score
5 0, 28 (35%), had a score of 1–2 and only 14 (17.5%) had a
score of at least 3 (p < 0.0001). Of the 23 spots with 0%
Cdx2 protein expression 20 had a simultaneous RNA ISH
score 5 0.
Comparing RNA ISH scores and DNA methylation (n 5
139 evaluable samples), an inverse, albeit weak correlation
was observed (r 5 20.11). Using 20% methylation as a cut-
off value, the correlation with RNA ISH was made. Again, an
inverse and signiﬁcant association between methylation and
RNA expression was noted with a higher RNA score more
frequently seen in cases with CDX2 methylation (p 5
0.0477).
Cdx2 expression in SSA and TA
To obtain better insight into the timing of Cdx2 protein
expression loss, 17 adenoma cases were retrieved including
included 7 SSAs, 9 TAs with low-grade dysplasia, and 1
mixed case of TA with a small focus of high-grade dysplasia
(5%)/SSA. Representative images are found in Supporting
Information Figure 3. All cases showed diffuse staining for
Cdx2 (>85% immunoreactive nuclei). However, the intensity
of Cdx2 staining in some SSAs was weaker in comparison to
TAs. This is especially highlighted by the case of mixed TA/
SSA showing a marked loss of Cdx2 intensity in the adjacent
focus of SSA.
Discussion
The novel ﬁndings of this study suggest that loss of Cdx2
expression may be involved in the serrated pathway to colo-
rectal cancer, as demonstrated by the high speciﬁcity for
BRAFV600E, CIMP-high and MMR-deﬁciency.
In a ﬁrst step, we investigated the loss of Cdx2 and clini-
copathological features with the aim of validating previous
ﬁndings. Cdx2 loss was associated with more aggressive
tumor features including higher tumor grade, more advanced
pT classiﬁcation, lymphatic invasion, and tumor budding.
Several studies underline similar correlations. In particular,
Ogino et al. using a tissue microarray of 621 patients show a
strong association of Cdx2 loss with female gender, right-
sided tumor location, advanced TNM stage, high tumor
grade, and mucinous or signet ring cell component.31 A pre-
vious study from our group on more than 1,000 patients
underlines these ﬁndings further with a loss of Cdx2
Figure 3. Cdx2 expression in a tissue microarray composed of eight colorectal cancer cell lines. The table outlines the different cell lines
with molecular features and Cdx2 expression. Panels a–h include images of each cell line and Cdx2 expression, by immunohistochemistry
(3200). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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expression associated with pT, pN, tumor grade, vascular
invasion, and right-sided location.30
It has been previously demonstrated that SSAs, impli-
cated as precursor lesions of the serrated pathway, display
loss of Cdx2 expression and often present with a gastric
phenotype.35 Such gastric differentiation may be the mor-
phological correlate of Cdx2 loss as an intestinal transcrip-
tion factor. Moreover, Cdx2 has been found to be
methylated in SSAs,36 however, to our knowledge, no corre-
lation between methylation status and protein expression
was made. We performed Cdx2 immunostaining on a small
set consisting of 10 tubular and/or tubulovilllous adenomas
and 7 SSAs. As expected, Cdx2 was strongly expressed in all
tubular adenomas. We were not able to reproduce the ﬁnd-
ings of Mochizuka et al. as all SSAs displayed diffuse Cdx2
staining but interestingly, we were able to observe distinctly
weaker staining of some SSAs in comparison to adenomas,
nicely highlighted in the case of a mixed TA/SSA. This sug-
gests that loss of Cdx2 may occur after the development of
SSA and prior to progression to carcinoma with loss of
staining intensity perhaps reﬂecting a “transitory” state.
Whether Cdx2 itself is directly and causally involved or may
Table 4. Association of Cdx2 methylation and clinicopathological features
Methylation
p value<20% 20%
Gender Male 80 (49.7) 6 (40.0) 0.5923
Female 81 (50.3) 9 (60.0)
Age (years) Mean 6 SD 67.6 6 11.1 69.1 6 13.0 0.3081
Size (cm) Mean 6 SD 4.6 6 1.9 4.7 6 2.6 0.9028
Tumor location Left 92 (57.1) 11 (73.3)
Right 21 (13.0) 2 (13.3) 0.3815
Rectum 48 (29.8) 2 (13.3)
Histological subtype Non-mucinous 140 (86.4) 15 (100.0) 0.2217
Mucinous 22 (13.6) 0 (0.0)
Tumor grade G1-2 103 (63.6) 10 (66.7) 1.0
G3 59 (36.4) 5 (33.3)
pT pT1-2 42 (25.9) 4 (26.7) 1.0
pT3-4 120 (74.1) 11 (73.3)
pN pN0 80 (49.4) 6 (40.0) 0.4867
pN1-2 82 (50.6) 9 (60.0)
pM pM0 143 (88.8) 12 (80.0) 0.3946
pM1 18 (11.2) 3 (20.0)
Venous invasion Presence 30 (18.2) 4 (26.7) 0.4887
Absence 135 (81.8) 11 (73.3)
Lymphatic invasion Presence 65 (40.1) 8 (53.3) 0.4127
Absence 97 (59.9) 7 (46.7)
Tumor budding Low-grade 92 (56.4) 10 (66.7) 0.4436
High-grade 71 (43.6) 5 (33.3)
MMR status Proficient 152 (92.1) 12 (80.0) 0.1349
Deficient 13 (7.9) 3 (20.0)
KRAS Wild-type 109 (66.5) 11 (73.3) 0.7762
Mutation 55 (33.5) 4 (26.7)
BRAF Wild-type 150 (92.0) 11 (73.3) 0.0184
V600E Mutation 13 (8.0) 4 (26.7)
CIMP Negative/low 89 (88.9) 8 (100.0) 0.5942
High 12 (11.2) 0 (0.0)
Cdx2 tumor Low (<20%) 10 (6.1) 4 (28.6) 0.0028
High (20%) 153 (93.9) 10 (71.4)
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act as a surrogate marker for these molecular changes
requires further elucidation.
In relation to molecular features, our results highlight
signiﬁcant and speciﬁc associations of Cdx2 loss with MMR-
deﬁciency, BRAFV600E mutation and CIMP-high. These ﬁnd-
ings agree with Baba and colleagues who demonstrate that
negative Cdx2 expression was associated with BRAF muta-
tion (64% mutated vs. 23% wild-type), MSI (57% MSI-high
vs. 23 and 34% MSS and MSI-low) and CIMP-high (67%
CIMP-high vs. 16 and 28% CIMP-negative and low).31 Walsh
et al. recently showed that reduced Cdx2 was very strongly
related to CIMP positivity (OR 5 5.2), BRAFV600E mutation
(OR 5 5.1), MLH1 methylation (OR 5 14.6) and MMR-
deﬁciency (OR 5 5.9) but not with KRAS mutation.37 Previ-
ous work by our group on more than 300 colorectal cancers
identiﬁed loss of Cdx2 expression in 23/24 BRAFV600E
mutated cases.32 In CIMP-high cancers, average Cdx2 expres-
sion was 35% in comparison to >80% in CIMP-negative and
–low cancers. As seen by Walsh, there was no association
with KRAS mutation.37 Here, we ﬁnd that loss of Cdx2 is
speciﬁc although not limited to MMR-deﬁcient cancers.
Looking at recent data from the Cancer Genome Atlas Net-
work, hypermethylation and CIMP-H phenotype includes,
but is not restricted to MSI positive colorectal cancers.38
Combined analysis of BRAFV600E/CIMP identiﬁed Cdx2 loss
as sensitive (80%) and speciﬁc (91.5%) for mutation/high.
These results were again conﬁrmed after analysis of Cdx2
expression in eight well-established cell lines. Cdx2 expression
could correctly predict BRAF and CIMP status in 6/8 tumors,
each. In the hierarchy of BRAF mutation, CIMP-high and
MSI-H, loss of CDX2 was predictive in all eight cell lines.
This study is also in line with the recent work by Melo
et al. who use a 146-gene classiﬁer to identify three colorectal
cancer subgroups CCS1, CCS2, and CCS3.39 They not only
ﬁnd an overrepresentation of BRAF mutated, MSI/CIMP1
cases in CCS3 but show evidence from SSAs, tubular adeno-
mas and other adenoma type suggesting that these CCS3
tumors may derive from the serrated pathway. Moreover,
they illustrate complete negative immunohistochemistry
staining for Cdx2 in tumors from CCS3.
We further investigated CDX2 hypermethylation as a
possible cause of protein loss. Indeed, a signiﬁcantly larger
number of patients showed Cdx2 loss in hypermethylated
cancers (29% vs. 6% in negative cases). Despite statistical
signiﬁcance however, the Cdx2 low expression in 10 out of
the 14 remaining tumors are not explained by hypermethyl-
ation. Moreover, we evaluated the RNA expression of
CDX2 by ISH and correlated gene expression with both
methylation and protein expression. A strong positive corre-
lation between protein and RNA expression was observed
by performing a spot-by-spot comparison across 485 tumor
spots (p < 0.0001). The expected negative correlation
between methylation and RNA expression was observed, but
was only weak in comparison. Taken together these results
seem to underline that DNA methylation of CDX2 may be
only one of several mechanisms explaining the loss of Cdx2
protein expression. Other mechanisms may exists such as
loss of heterozygosity (LOH),40 gene locus ampliﬁcation41
and MSI42 which have all been reported to regulate expres-
sion of CDX2. Additionally, CDX2 hypermethylation was
related to BRAFV600E but not to CIMP suggesting that
methylation of CDX2 may not be related to a more global
methylator phenotype. However, a more thorough investiga-
tion of CpG sites needs to be conducted in order to exclude
this hypothesis.
Because the assessment of CIMP for colorectal cancers has
yet to be standardized, our study may be limited by the deﬁ-
nition of CIMP used herein. Six genes, namely SOCS1, NEU-
ROG1, MLH1, CRABP1A, CDKN2A, and RUNX3 which are
standardly included into CIMP gene-panels were used for the
determination of CIMP status.20,43 Using a strict criterion for
CIMP status, 12% of patients were CIMP-high. This is on
the lower end of the expect range19,44 but consistent with
other European cohorts.7,13
To conclude, Cdx2 may play a role in the serrated path-
way to colorectal cancer as evidenced by strong relationships
with BRAFV600E, CIMP-high and MMR-deﬁciency. Under-
standing the mechanisms leading to Cdx2 loss could help to
elucidate whether Cdx2 is directly and functionally involved
in the progression of tumors through this pathway.
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